Kidney-specific Overexpression of Sirt1 Protects against Acute Kidney Injury by Retaining Peroxisome Function§

Received for publication, September 19, 2009, and in revised form, January 11, 2010 Published, JBC Papers in Press, February 5, 2010, DOI 10.1074/jbc.M109.067728

Kazuhiro Hasegawa‡, Shu Wakino‡‡, Kyoko Yoshioka‡, Satoru Tatematsu¶, Yoshikazu Hara‡, Hitoshi Minakuchi‡, Keiko Sueyasu‡, Naoki Washida‡, Hirobumi Tokuyama‡, Maty Tzukerman‡, Karl Skorecki‡, Koichi Hayashi‡, and Hiroshi Itoh‡

From the ‡Department of Internal Medicine, School of Medicine, Keio University, Tokyo 160-8582, Japan and the §Rappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology, Haifa 31096, Israel

Sirt1, a NAD-dependent protein deacetylase, is reported to regulate intracellular metabolism and attenuate reactive oxidative species (ROS)-induced apoptosis leading to longevity and acute stress resistance. We created transgenic (TG) mice with kidney-specific overexpression of Sirt1 using the promoter sodium-phosphate cotransporter IIa (Npt2) driven specifically in proximal tubules and investigated the kidney-specific role of Sirt1 in the protection against acute kidney injury (AKI). We also elucidated the role of number or function of peroxisome and mitochondria in mediating the mechanisms for renal protective effects of Sirt1 in AKI. Cisplatin-induced AKI decreased the number and function of peroxisomes as well as mitochondria and led to increased local levels of ROS production and renal tubular apoptotic cells. TG mice treated with cisplatin mitigated AKI, local ROS, and renal tubular apoptotic tubular cells. Consistent with these results, TG mice treated with cisplatin also exhibited recovery of peroxisome number and function, as well as rescued mitochondrial function; however, mitochondrial number was not recovered. Immunoelectron microscopic findings consistently demonstrated that the decrease in peroxisome number by cisplatin in wild type mice was restored in transgenic mice. In HK-2 cells, a cultured proximal tubule cell line, overexpression of Sirt1 rescued the cisplatin-induced cell apoptosis through the restoration of peroxisome number, although the mitochondria number was not restored. These results indicate that Sirt1 overexpression in proximal tubules rescues cisplatin-induced AKI by maintaining peroxisomes number and function, concomitant up-regulation of catalase, and elimination of renal ROS levels. Renal Sirt1 can be a potential therapeutic target for the treatment of AKI.

Sir2 (silent information regulator 2), a family of NAD-dependent protein deacetylases, can deacetylate various substrates involved in metabolism, acute stress resistance, and longevity (1). Sirt1, a mammalian homologue of Sir2, acts on several nuclear proteins, including p53 (2) and forkhead family proteins (FoxOs) (3), and prevents apoptosis. Calorie restriction or resveratrol, which activates Sirt1, is reported to protect from reactive oxygen species (ROS)-induced organ insult (4, 5). Additionally, the overexpression of Sirt1 itself also strengthens the stress resistance. For example, in mice with heart-specific Sirt1 overexpression, ROS-induced cardiac apoptosis was attenuated (6). Furthermore, we have recently demonstrated that Sirt1 in cultured proximal tubular cells alleviates H2O2-induced apoptosis (7). However, the direct relationship between kidney-specific Sirt1 and renal tissue survival in vivo has not been elucidated.

Several mechanisms have been suggested for the role of Sirt1 in apoptosis and/or oxidative stress. We have elucidated that Sirt1 activates catalase, which helps protect against ROS-induced injury (7). Transgenic (TG) mice overexpressing catalase in proximal renal tubular cells manifest attenuated renal tubular apoptosis (8). Liver-specific Sirt1 knock-out mice showed that Sirt1 activates fatty acid oxidation (FAO) (9). Because both peroxisomes and mitochondria play a significant role in FAO, and catalase is mainly localized in peroxisomes, it is surmised that Sirt1 also influences not only mitochondria but also peroxisomes. However, the direct relationship between Sirt1 and peroxisomes has not been examined thus far. Furthermore, Sirt1 has been reported to preserve mitochondrial function by inducing PGC-1α, which increases mitochondrial number (10). Because both peroxisome and mitochondrial functions are compromised by pathophysiological conditions, including cisplatin-induced (11, 12) and ischemic/reperfusion (I/R)-induced acute kidney injury (AKI) (13, 14), it is anticipated that Sirt1 is capable of alleviating renal injury by modulating peroxisome and mitochondrial function.

To examine the role of Sirt1 in renal tubules, we produced TG mice overexpressing Sirt1 specifically in proximal tubules. These mice were subjected to cisplatin- or I/R-induced AKI to investigate whether Sirt1 rescued renal insults. We also attempted to elucidate the role of peroxisome as well as mitochondria in mediating the mechanisms for the renal protective effects of Sirt1 in AKI.

1 To whom correspondence should be addressed: Dept. of Internal Medicine, School of Medicine, Keio University, 35 Shinnanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. Tel.: 81-3-5363-3796; Fax: 81-3-3359-2745; E-mail: swakino@sc.itc.keio.ac.jp.

2 The abbreviations used are: ROS, reactive oxidative species; TG, transgenic; AKI, acute kidney injury; WT, wild type; FAO, fatty acid oxidation; I/R, ischemic/reperfusion; BUN, blood urea nitrogen; mtDNA, mitochondrial DNA; PMP70, 70-kDa peroxisomal membrane protein; ACOX1, peroxisome acyl-CoA oxidase; MCAD, medium chain acyl-CoA dehydrogenase; PPAR, peroxisome proliferator-activated receptor; PGC-1α, PPARγ cofactor-1α; 4-HNE, 4-hydroxy-2(E)-nonenal; TUNEL, terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling; immuno-EM, immunoelectron microscopy; CR, calorie restriction; NC, normal chow; FACS, fluorescence-activated cell sorter; AQP4, aquaporin 4.
EXPERIMENTAL PROCEDURES

**Experimental Protocol for AKI**—Eight-week-old male mice were used in these experiments. For the induction of cisplatin-induced AKI, the mice were given intraperitoneal saline or cisplatin infusion (20 mg/kg/day; Sigma) for 3 days. On the third day, the kidney was harvested for histological analysis, and blood was taken for laboratory assay.

For the induction of I/R renal injury, the kidney was subjected to ischemia by clamping both renal pedicles for 60 min with vascular clips (Roboz, Gaithersburg, MD), during which the mice were kept at constant temperature (37 °C) with a warm blanket and well hydrated. Then the clip was removed, which allowed for reperfusion. After 24 h of renal ischemia, the kidney tissues were removed, and serum samples were obtained. A sham operation was performed by manipulation of the renal pedicles without clamping. Four animals from each respective genotype were used for each experiment. Serum levels of blood urea nitrogen (BUN) and creatinine were measured with Fujifilm DRI-CHEM3500V autoanalyzer (Fuji Photo Film). These studies as well as the following animal studies were performed in accordance with the animal experimentation guidelines of Keio University School of Medicine.

**Experimental Protocol for Calorie Restriction**—Calorie restriction was performed as described previously (15). Ten male C57BL/6 mice were randomly assigned to two groups of five. From two months of age, one group was fed normal chow, and the other group was put on a caloric restriction diet (70% of calorie intake adjusted to body weight) for three months. At the end of five months, the effects of cisplatin on the kidneys from calorie-restricted mice were evaluated. The mice were sacrificed, and the kidneys were removed for use in immunoblotting and histological experiments as described below.

**Plasmids and Constructs**—Human Sirt1 cDNA containing its full-length open reading frame was cloned as described previously (16). In constructing the transgenic vector including human kidney cDNA as a positive control. C, Southern blotting shows the introduction of Sirt1 transgene in mice of line 001 and 104. An arrow indicates a band corresponding to transgene-derived Sirt1. D, Immunoblotting for Sirt1 indicates that TG mice express approximately five times the level of Sirt1 as compared with WT mice. E, Sirt1 expressions in various tissues from TG mice. F, Immunohistochemical localization of Sirt1 shows predominant expression in proximal tubules in kidneys of TG mice. Kidneys from TG and WT mice were immunostained for FLAG epitope as described under "Experimental Procedures." Original magnification was ×100 (LPF) or ×400 (HPF). Scale bars indicate 500 μm (low power field; LPF) and 100 μm (high power field; HPF). G, Kidneys from mice overexpressing Sirt1 demonstrate that Sirt1 is overexpressed preferentially in the cortical area (proximal S1 + S2 segments). The immunohistological examination reveals no overlap between Sirt1 and AQP4 staining areas (proximal S3 segments). They are from sequential sections labeled with anti-Sirt1 and anti-AQP4 antibody. Scale bar, 500 μm.

**EXPERIMENTAL PROCEDURES**

**Experimental Protocol for AKI**—Eight-week-old male mice were used in these experiments. For the induction of cisplatin-induced AKI, the mice were given intraperitoneal saline or cisplatin infusion (20 mg/kg/day; Sigma) for 3 days. On the third day, the kidney was harvested for histological analysis, and blood was taken for laboratory assay.

For the induction of I/R renal injury, the kidney was subjected to ischemia by clamping both renal pedicles for 60 min with vascular clips (Roboz, Gaithersburg, MD), during which the mice were kept at constant temperature (37 °C) with a warm blanket and well hydrated. Then the clip was removed, which allowed for reperfusion. After 24 h of renal ischemia, the kidney tissues were removed, and serum samples were obtained. A sham operation was performed by manipulation of the renal pedicles without clamping. Four animals from each respective genotype were used for each experiment. Serum levels of blood urea nitrogen (BUN) and creatinine were measured with Fujifilm DRI-CHEM3500V autoanalyzer (Fuji Photo Film). These studies as well as the following animal studies were performed in accordance with the animal experimentation guidelines of Keio University School of Medicine.

**Experimental Protocol for Calorie Restriction**—Calorie restriction was performed as described previously (15). Ten male C57BL/6 mice were randomly assigned to two groups of five. From two months of age, one group was fed normal chow, and the other group was put on a caloric restriction diet (70% of calorie intake adjusted to body weight) for three months. At the end of five months, the effects of cisplatin on the kidneys from calorie-restricted mice were evaluated. The mice were sacrificed, and the kidneys were removed for use in immunoblotting and histological experiments as described below.

**Plasmids and Constructs**—Human Sirt1 cDNA containing its full-length open reading frame was cloned as described previously (16). In constructing the transgenic vector including human kidney cDNA as a positive control. C, Southern blotting shows the introduction of Sirt1 transgene in mice of line 001 and 104. An arrow indicates a band corresponding to transgene-derived Sirt1. D, Immunoblotting for Sirt1 indicates that TG mice express approximately five times the level of Sirt1 as compared with WT mice. E, Sirt1 expressions in various tissues from TG mice. F, Immunohistochemical localization of Sirt1 shows predominant expression in proximal tubules in kidneys of TG mice. Kidneys from TG and WT mice were immunostained for FLAG epitope as described under "Experimental Procedures." Original magnification was ×100 (LPF) or ×400 (HPF). Scale bars indicate 500 μm (low power field; LPF) and 100 μm (high power field; HPF). G, Kidneys from mice overexpressing Sirt1 demonstrate that Sirt1 is overexpressed preferentially in the cortical area (proximal S1 + S2 segments). The immunohistological examination reveals no overlap between Sirt1 and AQP4 staining areas (proximal S3 segments). They are from sequential sections labeled with anti-Sirt1 and anti-AQP4 antibody. Scale bar, 500 μm.

**EXPERIMENTAL PROCEDURES**

**Experimental Protocol for AKI**—Eight-week-old male mice were used in these experiments. For the induction of cisplatin-induced AKI, the mice were given intraperitoneal saline or cisplatin infusion (20 mg/kg/day; Sigma) for 3 days. On the third day, the kidney was harvested for histological analysis, and blood was taken for laboratory assay.

For the induction of I/R renal injury, the kidney was subjected to ischemia by clamping both renal pedicles for 60 min with vascular clips (Roboz, Gaithersburg, MD), during which the mice were kept at constant temperature (37 °C) with a warm blanket and well hydrated. Then the clip was removed, which allowed for reperfusion. After 24 h of renal ischemia, the kidney tissues were removed, and serum samples were obtained. A sham operation was performed by manipulation of the renal pedicles without clamping. Four animals from each respective genotype were used for each experiment. Serum levels of blood urea nitrogen (BUN) and creatinine were measured with Fujifilm DRI-CHEM3500V autoanalyzer (Fuji Photo Film). These studies as well as the following animal studies were performed in accordance with the animal experimentation guidelines of Keio University School of Medicine.

**Experimental Protocol for Calorie Restriction**—Calorie restriction was performed as described previously (15). Ten male C57BL/6 mice were randomly assigned to two groups of five. From two months of age, one group was fed normal chow, and the other group was put on a caloric restriction diet (70% of calorie intake adjusted to body weight) for three months. At the end of five months, the effects of cisplatin on the kidneys from calorie-restricted mice were evaluated. The mice were sacrificed, and the kidneys were removed for use in immunoblotting and histological experiments as described below.

**Plasmids and Constructs**—Human Sirt1 cDNA containing its full-length open reading frame was cloned as described previously (16). In constructing the transgenic vector including human kidney cDNA as a positive control. C, Southern blotting shows the introduction of Sirt1 transgene in mice of line 001 and 104. An arrow indicates a band corresponding to transgene-derived Sirt1. D, Immunoblotting for Sirt1 indicates that TG mice express approximately five times the level of Sirt1 as compared with WT mice. E, Sirt1 expressions in various tissues from TG mice. F, Immunohistochemical localization of Sirt1 shows predominant expression in proximal tubules in kidneys of TG mice. Kidneys from TG and WT mice were immunostained for FLAG epitope as described under "Experimental Procedures." Original magnification was ×100 (LPF) or ×400 (HPF). Scale bars indicate 500 μm (low power field; LPF) and 100 μm (high power field; HPF). G, Kidneys from mice overexpressing Sirt1 demonstrate that Sirt1 is overexpressed preferentially in the cortical area (proximal S1 + S2 segments). The immunohistological examination reveals no overlap between Sirt1 and AQP4 staining areas (proximal S3 segments). They are from sequential sections labeled with anti-Sirt1 and anti-AQP4 antibody. Scale bar, 500 μm.
obtained from superovulated C57BL/6 × C3H mice (see Fig.
1A) (18). Founder mice were identified by Southern blot analysis
of KpnI/EcoRI-digested tail genomic DNA with the human Sirt1 cDNA as a probe. The PCR primers for making Southern blot probes are listed in supplemental Table SI. The positive TG founders were then crossed with wild type C57BL/6 mice (Charles River Japan Inc.) to obtain the F1 generation. Genomic DNA was isolated from tail biopsies at 3 weeks of age using a DNeasy kit (Qiagen) and subjected to Southern blot analysis to identify the transgene. Southern blots were performed using a 32P-labeled probe of human Sirt1 cDNA. Genomic DNA digested by KpnI and EcoRI yielded a single band of the expected size in TG mice only (see Fig. 1C). Additional screening of genomic DNA samples was performed by polymerase chain reaction using the transgene-specific oligonucleotide primers CTATGCTGAGGCCCTAGGTTT (Npt2 promoter side) and GTCGTCGTCGCCCTAGTGCAGTTG (Sirt1 gene side) (see Fig. 1A), which amplify a 1310-bp region spanning the junction between the Npt2 promoter and the Sirt1 gene (see Fig. 1B). We used the transgenic vector as a positive control.

Quantification of Mitochondrial DNA (mtDNA)—Total RNA from mouse kidneys were prepared as described previously (19). The LightCycler Instrument (Roche Applied Science) was used for the quantification of mtDNA with hybridization probes in a total volume of 20 μl, containing 0.5 μM of each primer, 0.2 μM of each probe, 5 mm MgCl2, 2 μl of Light Cycler-DNA Master hybridization probes (Roche Applied Science), and 20 ng of DNA. The cycling conditions were set as follows: initial denaturation 95 °C for 30 s (temperature transition rate, 20 °C/s) followed by 45 cycles of 95 °C for 0 s (20 °C/s), 53 °C for 5 s (20 °C/s), and 72 °C for 11 s (2 °C/s). The standard curve was calculated by analyzing serial dilutions (0.64–5.0 × 104 pg/μl) of plasmid DNA inserted with the target PCR product. The mtDNA contents of kidney tissues were normalized to the total amount of DNA in each sample. The primers and probes were as follows: sense primer, 5′-ACCATTGTGCA-GACGCCATAA-3′; antisense primer, 5′-TGAAATGTGTTT-GGGCTACGG-3′; 5′-fluorescein-labeled anchor probe, 5′-CATCTAGCTATCATGTTAATCTCATT-3′; and 5′-LC Red 640-labeled sensor probe, 5′-TGATCAGGATGACCT-CAAAATCCLAAT-3′. These primers and probes were designed to amplify the mouse mtDNA designed in reference to the *Mus musculus* mitochondrion genome and not to amplify the mtDNA-like sequence in the nuclear genome.

**Immunoblotting**—Immunoblotting was performed as described previously (19) using specific antibodies against Sirt1 (Millipore, Bedford, MA), catalase (Calbiochem, La Jolla, CA), 70-kDa peroxisomal membrane protein (PMP70; Affinity Bioreagents, Golden, CO), peroxisome acyl-CoA oxidase (ACOX1; Abcam Inc, Cambridge, MA), medium chain acyl-CoA dehydrogenase (MCAD; Cayman Chemicals, Ann Arbor, MI), and PPARγ cofactor-1α (PGC-1α; Santa Cruz Biotechnology, Santa Cruz, CA). The anti-Sirt1 antibody was generated from rabbit and recognizes both human and mouse Sirt1. The β-actin band recognized by specific antibody (Sigma) was used as a loading control. For immunoblotting, 30 μg of protein from each sample was loaded into the individual lanes of the gels.

**Immunohistochemistry**—Four-μm paraffin sections of kidneys were used to stain for aquaporin 4 (AQP4), 4-hydroxy-2(E)-nonenal (4-HNE), Sirt1, and FLAG, using primary antibodies including anti-AQP4 antibody (Santa Cruz Biotechnology), 4-HNE (Japan Institute for the Control of Aging), Sirt1 (Millipore, Bedford, MA), and FLAG (Sigma). Tissue sections of 4-μm thickness were obtained and fixed in 3% formaldehyde in phosphate-buffered saline for 15 min at room temperature and treated as described previously (20). Briefly, the sections were sequentially blocked for endogenous biotin binding using a Vector blocking kit (Vector Laboratories, Burlingame, CA) and for endogenous peroxidase activity with 1.5% H2O2. After incubation with preimmune or immune sera overnight, the sections were stained with biotin-labeled goat anti-rabbit IgG (Vector) or biotin-labeled anti-mouse IgG (Vector) and then treated with the Vectastain Elite ABC Kit (Vector). The slides were washed with HBSS-HEPES and developed with 3,3′-diaminobenzidine tetrahydrochloride substrate (0.5 mg/ml) in 0.05 mol/liter HEPES (HBSS-HEPES) with 0.1% saponin. Nonspecific binding was blocked with 10% normal goat serum. After incubation with preimmune or immune sera overnight, the sections were stained with biotin-labeled goat anti-rabbit IgG (Vector) or biotin-labeled anti-mouse IgG (Vector) and then treated with the Vectastain Elite ABC Kit (Vector). The slides were washed with HBSS-HEPES and developed with 3,3′-diaminobenzidine tetrahydrochloride substrate (0.5 mg/ml) in 0.05 mol/l Tris, pH 7.4, 0.0075% H2O2 (Sigma).

**RNA Isolation, Reverse Transcription, and Quantitative PCR**—Total RNA was isolated using TRIzol reagent (Invitrogen). RNA (400 ng) was reverse transcribed to cDNA using the SuperScript II

---

**Figure 2. Effects of cisplatin on renal histology and apoptotic process.** A, renal histological changes induced by cisplatin-induced acute kidney injury. An arrowhead indicates the areas of cisplatin-induced damages. Scale bar, 100 μm. B, TUNEL-positive cells are detected in cortical areas, which barely overlap with areas containing cells expressing AQP4 (a marker for proximal S3 segments) in mice treated with cisplatin. They are from sequential sections labeled with anti-AQP4 antibody and stained with TUNEL. Scale bar, 200 μm. **Renal Sirt1 Protects against Acute Kidney Injury**
RNase H-Reverse Transcriptase system (Invitrogen), and specific transcripts were quantitated by real-time PCR using the ABI Prism 7700 sequence detection system (Applied Biosystems, Foster City, CA) and the SYBR GREEN system (Applied Biosystems). Sequences of the primers are listed in supplemental Tables SII and SIII. The relative mRNA levels for the specific genes were normalized to 28S rRNA levels. The reference gene (28S rRNA) was not affected by cisplatin treatment.

Renal Histology—After the kidneys were removed, they were fixed in 4% parformaldehyde for paraffin embedding. Paraffin-embedded tissues were sectioned at 4 μm for hematoxylin and eosin staining. Renal histology was examined in a blinded fashion. The following histological changes were evaluated: the percentage of renal tubules that displayed cell lysis, the loss of brush border, and cast formation. The development of tissue damage was scored as follows: 0, no damage; 1, <25% damage; 2, 25–50% damage; 3, 50–75% damage; 4, >75% damage. Pictures of representative fields were also recorded.

TUNEL Assay—Apoptosis of renal tubular cells was identified by TUNEL assay as described previously (18) with an in situ cell death detection kit (Roche Applied Science).

Quantification of Peroxisomes and Mitochondria by Immunoelectron Microscopy—For postembedding immunoelectron microscopy (immuno-EM), sliced kidney sections were fixed for 1 h at room temperature with 4% formaldehyde and 0.25% glutaraldehyde in 0.1 M HEPES/NaOH, pH 7.4. After rapid dehydration in ethanol, the sections were embedded in LR White embedding resin. Thin sections on nickel grids were preincubated on a drop of 0.5% bovine serum albumin in phosphate-buffered saline. The sections were incubated overnight in the 1/1000 diluted primary antibody, an anti-PMP70 antibody. After being rinsed with phosphate-buffered saline, the sections were incubated for 30 min on a drop of protein A-gold (15 nm) prepared as described previously (21). The sections were briefly contrasted with uranyl acetate and lead citrate before examination. Eight random ultrastructural photomicrographs taken on the microscopic fields corresponding to the kidney cortex area from each mice at a magnification of ×12,800 were chosen for observation. Then peroxisomes and mitochondria were numbered. By the above postembedding protein A gold labeling, anti-PMP70 antibody gave specific signals on the membranes of peroxisomes, whereas mitochondria were negative on staining with the anti-PMP70 antibody.

**FIGURE 3. Effects of kidney-specific Sirt1 overexpression on renal function and histology in cisplatin-induced acute kidney injury.** A and B, WT or TG mice were treated with cisplatin as described under “Experimental Procedures.” Serum levels of BUN (A) and creatinine (B) were measured 3 days after cisplatin injection. C, representative hematoxylin-eosin staining of kidney sections from WT and TG mice in cisplatin-induced AKI. An arrowhead represents lysed tubules. Pathological scores of tubular damages as described under “Experimental Procedures” are shown in the lower panel. Scale bar, 100 μm. D, representative images of the TUNEL assay show cisplatin-induced renal tubular cell apoptosis in WT mice, which is attenuated in TG mice. An arrow indicates TUNEL-positive cells with condensed or fragmented nuclei. The numbers of TUNEL-positive cells are shown in the lower panel. Scale bar, 100 μm. *, p < 0.05 versus saline-infused WT mice; **, p < 0.01 versus saline-infused WT mice; †, p < 0.05 versus saline-infused TG mice; ††, p < 0.01 versus saline-infused TG mice; §, p < 0.05 versus cisplatin-infused WT mice; §§, p < 0.01 versus cisplatin-infused WT mice (n = 4).
Renal Sirt1 Protects against Acute Kidney Injury

HK2 cells were determined with the aid of the fluorescent dyes: Organelle Lights Peroxi-GFP and Organelle Lights Mito-OFP (Molecular Probes, Eugene, OR), respectively, following the manufacturer’s instructions. For microscopic analysis, the HK2 cells were stained with the fluorescent probes and observed with a confocal microscope (LSM 510; Carl Zeiss, Oberkochen, Germany). In apoptosis measurements, annexin V-fluorescein isothiocyanate in combination with propidiumidine was used to quantitatively determine the percentage of cells undergoing apoptosis, as described previously (7).

Statistics—The data were expressed as the means ± S.E. The data were analyzed using one-way or two-way analysis of variance, as appropriate, followed by a Bonferroni’s multiple comparison post hoc test. p values less than 0.05 were considered statistically significant.

RESULTS

Generation of Renal Epithelium-specific Sirt1 TG Mice—We generated TG mice with proximal tubule-specific overexpression of human Sirt1 by using Npt2 promoter (Fig. 1A). Positive TG mice were identified with PCR and confirmed by Southern blot (Fig. 1, B and C). We obtained two lines of TG mice, line 001 and line 104. The expression levels of Sirt1 in the kidney were similar between the two lines, and both lines developed normally and appeared to have the same phenotype. We used line 001 for subsequent experiments and showed the data below for the line 001. Immunoblotting showed that the Sirt1 band of TG mice was broad and composed of one band for endogenous Sirt1 (100 kDa) and one for FLAG-tagged human Sirt1 (101 kD) (Fig. 1D). The protein expression levels of Sirt1 in TG mice were increased as compared with those in WT mice (Fig. 1D). TG mice were phenotypically normal and fertile. The overexpression of human Sirt1 in the kidney and other tissues was confirmed by immunoblotting (Fig. 1E and supplemental Fig. SI). Immunohistochemistry showed that exogenous transgene was overexpressed especially in the nucleus of renal tubular cells. (Fig. 1F). Sirt1 was localized preferentially in the cortical area, mostly likely in proximal S1 and S2 segments. In contrast, immunohistochemistry for Sirt1 revealed only modest staining in the medullary segments, and there was less overlap with the AQP4-expressing S3 segment area (Fig. 1G).

Tissue Culture—HK2 cells were cultured as previously described (7). The expression plasmid containing Sirt1 cDNA (pcDNA3.1-Sirt1) and the control plasmid (pcDNA3.1) were transfected into HK-2 cells by using Lipofectamine 2000 (Invitrogen) as described previously (7). Forty-eight hours after the transfection, the cells were used for the following experiments. Sirt1-transfected HK-2 cells were treated with or without cisplatin or I/R. Cisplatin was used at a dilution of 50 μM for 24 h in Dulbecco’s modified Eagle’s medium. In vitro I/R experiments, HK-2 cells (~80% confluent) were washed in glucose-free buffer (154 mM NaCl, 5.6 mM KCl, 2.3 mM CaCl₂, 1.0 mM MgCl₂, 3.6 mM NaHCO₃, and 5 mM HEPES, pH 7.2) and then incubated with 10 mM antimycin A plus 10 mM 2-deoxyglucose plus 1 μM calcium ionophore (A23187) for 60 min (to induce ischemic injury in vitro). After this ischemic period, in vitro reperfusion was achieved by incubating cells in glucose-replete complete growth medium. Twelve hours later, the cells were harvested and subjected to the following study. The peroxisomal mass and the mitochondrial mass of

HK2 cells were determined with the aid of the fluorescent dyes: Organelle Lights Peroxi-GFP and Organelle Lights Mito-OFP (Molecular Probes, Eugene, OR), respectively, following the manufacturer’s instructions. For microscopic analysis, the HK2 cells were stained with the fluorescent probes and observed with a confocal microscope (LSM 510; Carl Zeiss, Oberkochen, Germany). In apoptosis measurements, annexin V-fluorescein isothiocyanate in combination with propidiumidine was used to quantitatively determine the percentage of cells undergoing apoptosis, as described previously (7).

Statistics—The data were expressed as the means ± S.E. The data were analyzed using one-way or two-way analysis of variance, as appropriate, followed by a Bonferroni’s multiple comparison post hoc test. p values less than 0.05 were considered statistically significant.

RESULTS

Generation of Renal Epithelium-specific Sirt1 TG Mice—We generated TG mice with proximal tubule-specific overexpression of human Sirt1 by using Npt2 promoter (Fig. 1A). Positive TG mice were identified with PCR and confirmed by Southern blot (Fig. 1, B and C). We obtained two lines of TG mice, line 001 and line 104. The expression levels of Sirt1 in the kidney were similar between the two lines, and both lines developed normally and appeared to have the same phenotype. We used line 001 for subsequent experiments and showed the data below for the line 001. Immunoblotting showed that the Sirt1 band of TG mice was broad and composed of one band for endogenous Sirt1 (100 kDa) and one for FLAG-tagged human Sirt1 (101 kD) (Fig. 1D). The protein expression levels of Sirt1 in TG mice were increased as compared with those in WT mice (Fig. 1D). TG mice were phenotypically normal and fertile. The overexpression of human Sirt1 in the kidney and other tissues was confirmed by immunoblotting (Fig. 1E and supplemental Fig. SI). Immunohistochemistry showed that exogenous transgene was overexpressed especially in the nucleus of renal tubular cells. (Fig. 1F). Sirt1 was localized preferentially in the cortical area, mostly likely in proximal S1 and S2 segments. In contrast, immunohistochemistry for Sirt1 revealed only modest staining in the medullary segments, and there was less overlap with the AQP4-expressing S3 segment area (Fig. 1G).
Renal Sirt1 Protects against Acute Kidney Injury

Cisplatin-induced AKI—After cisplatin injection, AKI developed with elevations in both BUN (166 ± 22 mg/dl, versus 21 ± 6 mg/dl, p < 0.01) and serum creatinine levels (2.7 ± 0.2 mg/dl versus 0.3 ± 0.1 mg/dl, p < 0.01) with renal tubular damage (Fig. 2A). Furthermore, TUNEL staining showed marked tubular cell apoptosis, particularly in cortical segments (Fig. 2B, left panel), which were adjacent to the AQP4-stained S3 segment of proximal tubules (Fig. 2B, right panel) (22). These data indicated that the areas affected by cisplatin in our experiment were predominantly localized in the S1+S2 segments.

Protective Effects of Sirt1 Overexpression on Cisplatin-induced AKI—The renal protective role of Sirt1 in cisplatin-induced AKI was examined in TG mice. The injection of cisplatin provoked AKI in WT mice, but AKI was partially ameliorated in TG mice (BUN, 83 ± 10 mg/dl; creatinine, 1.6 ± 0.4 mg/dl; Fig. 3, A and B, respectively). Concordantly, the renal histological changes induced by cisplatin were rescued in TG mice as evaluated by the pathological scores (Fig. 3C). To determine the effects of Sirt1 overexpression on renal cell apoptosis, we performed TUNEL staining. No TUNEL-positive cells were detected in both WT mice and TG mice with saline injection (Fig. 3D). In WT mice, cisplatin treatment resulted in an increase in TUNEL-positive cells (Fig. 3D, arrows), which was ameliorated in TG mice (TUNEL-positive cells, 35 ± 3/mm² versus 18 ± 3/mm² for WT and TG mice, respectively).

Effects of Sirt1 Overexpression on Peroxisome Function in Cisplatin-induced AKI—Cisplatin has been reported to decrease peroxisome number and impair its function (11), which contributes to the renal damage. To elucidate the role of Sirt1 in these changes, we examined the protein expression levels of PMP70, a marker for the number of peroxisome, as well as the levels of catalase and ACOX1, markers for peroxisomal function. As shown in Fig. 4A, cisplatin-treated mice exhibited ~70% reduction in PMP70 protein, which were restored in TG mice. Similar results were obtained with the expression levels of catalase (Fig. 4B) and ACOX1 (Fig. 4C). Consistently, the formation of 4-HNE was enhanced in proximal tubules in WT mice after cisplatin treatment (Fig. 4D). These changes were attenuated in TG mice with cisplatin insults. These staining patterns were compatible with the results of pathological findings and TUNEL assay (Fig. 3, C and D, respectively).

Effects of Sirt1 Overexpression on Mitochondrial Number and Function in Cisplatin-induced AKI—As shown in Fig. 5A, cisplatin caused only a modest, albeit significant, decrease in mtDNA amounts (i.e. 13% reduction). Furthermore, the reduced mtDNA number was not restored in TG mice. The expression levels of PGC-1α, a key molecule for mitochondria proliferation, were markedly decreased in cisplatin-treated mice and were not ameliorated in TG mice (Fig. 5B). Cisplatin has also been reported to reduce the pro-
tein expression of MCAD, a rate-limiting enzyme in FAO in mitochondria. Similarly, a 52% decrease in MCAD expression was observed in WT mice compared with that in saline-injected mice (Fig. 5C). However, this alteration was partially reversed in TG mice.

Effects of Sirt1 Overexpression on the Activation of Downstream Transcription Factors—Sirt1 regulates the activities of various transcription factors involved in mitochondrial and peroxisomal function, including PPARα, PPARγ, and PGC-1α. The mRNA expressions of target genes of these molecules were examined by quantitative reverse transcription-PCR (supplemental Fig. SII). The mRNA levels of PPARα target genes, fatty acid transport proteins, and CYP4a10 were not affected by cisplatin treatment, which were not altered in TG mice, either. However, the mRNA levels of other PPARα target molecules, such as CPT1α, CPT1β, and (supplemental Fig. V4) were down-regulated by cisplatin, which were partially rescued in TG mice similarly with MCAD. The mRNA levels of PPARγ target genes, glycerol kinase, and glycerol-3-phosphate acetyltransferase were not altered by cisplatin treatment or by overexpression of Sirt1, which indicated that cisplatin-induced renal damages had no effect on PPARγ activity (supplemental Fig. SII). Consistent with the results of protein expression of PGC-1α (Fig. 5B), the mRNA levels of PGC-1α target genes (Atp5g1 and Cox5a) were decreased in WT mice treated with cisplatin and were not rescued in TG mice (supplemental Fig. SII).

Quantification of Peroxisome and Mitochondria on Immuno-EM in Cisplatin-induced AKI—To identify the peroxisomal or mitochondrial number in proximal tubular cells, immuno-EM was performed in the kidneys of WT and TG mice. The peroxisome membranes were positively stained with anti-PMP70 antibody, which allowed us to distinguish them from mitochondria. As shown in Fig. 6, both the number and the morphology of peroxisomes in WT mice treated with cisplatin also changed; they were small with a serrated or indented contour. These morphological deformities were not observed in TG mice (Fig. 6A). Both the number and the morphology of mitochondria were not different between WT mice and TG mice with saline infusion. The insults with cisplatin slightly decreased the number of mitochondria in WT mice and were not reversed in TG mice (supplemental Fig. SII).

FIGURE 7. Calorie restriction induced Sirt1 in the renal proximal tubules. A, immunostaining with an anti-Sirt1 antibody shows increased Sirt1 staining in proximal tubules in mice on CR as compared with those in mice on NC. Scale bar, 50 μm. B, immunoblotting showed that Sirt1 protein expression was increased in kidneys of mice under CR for three months. *, p < 0.05 versus mice with NC (n = 4). C and D, effects of calorie restriction on cisplatin-induced acute kidney injury were examined as described under “Experimental Procedures.” In mice on CR diet, the cisplatin-induced acute kidney injury was partially prevented, compared with that in mice on NC. Scale bar, 100 μm. The arrowheads indicate the areas of cisplatin-induced tissue damages. E and F, immunostaining against 4-HNE, a toxic lipid peroxidation product generated by the local H2O2, was prominent in mice on NC, but was diminished in mice on CR. Scale bar, 50 μm.

Renal Sirt1 Protects against Acute Kidney Injury
Effects of Calorie Restriction on Sirt1 Expression and Cisplatin-induced AKI—Because Sirt1 is an important factor that mediates the beneficial effects of calorie restriction (CR), we examined Sirt1 expression in the kidneys of mice on a 3-month CR diet. Immunohistochemistry in the kidneys in WT mice showed that there is clear nuclear staining in glomeruli and both nuclear and cytoplasmic staining in proximal tubules in WT mice. On the other hand, only faint expression of Sirt1 was detected in the distal tubules. As shown in the immunohistochemistry of the kidneys after CR (Fig. 7A), CR increases the Sirt1 expression in proximal tubules, whereas the Sirt1 expressions in glomeruli were not altered. Immunoblotting showed that renal Sirt1 expression was doubled in mice on CR as compared with that in mice fed normal chow (NC) (Fig. 7B). The renal protective role of CR in cisplatin-induced AKI was examined. In mice on NC, cisplatin aggravated renal function (BUN; 168 ± 21 versus 22 ± 4 mg/dl, p < 0.01, creatinine; 2.8 ± 0.3 versus 0.3 ± 0.1 mg/dl, p < 0.01) and produced marked renal histological changes. In contrast, in mice fed a CR diet, the changes in renal function were partially ameliorated (BUN, 115 ± 24 versus 19 ± 4 mg/dl, p < 0.01; creatinine, 2.1 ± 0.3 versus 0.3 ± 0.1 mg/dl, p < 0.01). Consistently, the renal histological changes induced by cisplatin were rescued significantly as compared with those in mice on NC (Fig. 7, C and D). Fig. 7E illustrates the effects of cisplatin on the production of 4-HNE in mice on NC and CR diets. Cisplatin markedly increased renal 4-HNE production in mice fed NC, which was partially restored in mice on a CR diet (Fig. 7, E and F). We further examined the effects of CR on the activation of downstream transcription factors of Sirt1 by quantitative reverse transcription-PCR. The mRNA expression of PPARα, PPARγ, and PGC-1α target genes, including MCAD and ACOX-1 was analyzed. These results were similar to those obtained in cisplatin-induced renal damages in TG mice (supplemental Figs. SIII and SIV).

Effects of Renal I/R Injury in Sirt1-TG Mice—We next examined the role of Sirt1 in renal I/R injury. Extensive tubular injuries were observed in WT kidneys 24 h after I/R. Overexpression of Sirt1, however, failed to protect against I/R injury. Neither renal function, as assessed by BUN and serum creatinine (Fig. 8A), nor renal histological findings were alleviated in Sirt1-TG mice, as compared with WT mice (Fig. 8B). Fig. 8C shows the effects of Sirt1 on the apoptotic process induced by I/R-induced AKI. Thus, I/R-induced TUNEL-positive cells were observed predominantly in the medulla rather than in the renal cortex, i.e. preferentially in S3 segmental proximal tubules rather than in cortical proximal S1 or S2 segments. Kidneys in TG mice after I/R had nearly the same amount of TUNEL-positive cells as in WT mice (14.3 ± 3.2 versus 13.7 ± 3.8 nuclei/high power field). In the immunofluorescence (IF), the number of peroxisomes was not affected by I/R, which were also unaltered in TG mice. On the other hand, the number of mitochondria was reduced by I/R, which was not ameliorated in TG mice. We next examined the role of Sirt1 in renal I/R injury. Extensive tubular injuries were observed in WT kidneys 24 h after I/R. Overexpression of Sirt1, however, failed to protect against I/R injury. Neither renal function, as assessed by BUN and serum creatinine (Fig. 8A), nor renal histological findings were alleviated in Sirt1-TG mice, as compared with WT mice (Fig. 8B). Fig. 8C shows the effects of Sirt1 on the apoptotic process induced by I/R-induced AKI. Thus, I/R-induced TUNEL-positive cells were observed predominantly in the medulla rather than in the renal cortex, i.e. preferentially in S3 segmental proximal tubules rather than in cortical proximal S1 or S2 segments. Kidneys in TG mice after I/R had nearly the same amount of TUNEL-positive cells as in WT mice (14.3 ± 3.2 versus 13.7 ± 3.8 nuclei/high power field). In the immunofluorescence (IF), the number of peroxisomes was not affected by I/R, which were also unaltered in TG mice. On the other hand, the number of mitochondria was reduced by I/R, which was not ameliorated in TG mice. We next examined the role of Sirt1 in renal I/R injury. Extensive tubular injuries were observed in WT kidneys 24 h after I/R. Overexpression of Sirt1, however, failed to protect against I/R injury. Neither renal function, as assessed by BUN and serum creatinine (Fig. 8A), nor renal histological findings were alleviated in Sirt1-TG mice, as compared with WT mice (Fig. 8B). Fig. 8C shows the effects of Sirt1 on the apoptotic process induced by I/R-induced AKI. Thus, I/R-induced TUNEL-positive cells were observed predominantly in the medulla rather than in the renal cortex, i.e. preferentially in S3 segmental proximal tubules rather than in cortical proximal S1 or S2 segments. Kidneys in TG mice after I/R had nearly the same amount of TUNEL-positive cells as in WT mice (14.3 ± 3.2 versus 13.7 ± 3.8 nuclei/high power field). In the immunofluorescence (IF), the number of peroxisomes was not affected by I/R, which were also unaltered in TG mice. On the other hand, the number of mitochondria was reduced by I/R, which was not ameliorated in TG mice.

**Effects of Calorie Restriction on Sirt1 Expression and Cisplatin-induced AKI**—Because Sirt1 is an important factor that mediates the beneficial effects of calorie restriction (CR), we examined Sirt1 expression in the kidneys of mice on a 3-month CR diet. Immunohistochemistry in the kidneys in WT mice showed that there is clear nuclear staining in glomeruli and both nuclear and cytoplasmic staining in proximal tubules in WT mice. On the other hand, only faint expression of Sirt1 was detected in the distal tubules. As shown in the immunohistochemistry of the kidneys after CR (Fig. 7A), CR increases the Sirt1 expression in proximal tubules, whereas the Sirt1 expressions in glomeruli were not altered. Immunoblotting showed that renal Sirt1 expression was doubled in mice on CR as compared with that in mice fed normal chow (NC) (Fig. 7B). The renal protective role of CR in cisplatin-induced AKI was examined. In mice on NC, cisplatin aggravated renal function (BUN; 168 ± 21 versus 22 ± 4 mg/dl, p < 0.01, creatinine; 2.8 ± 0.3 versus 0.3 ± 0.1 mg/dl, p < 0.01) and produced marked renal histological changes. In contrast, in mice fed a CR diet, the changes in renal function were partially ameliorated (BUN, 115 ± 24 versus 19 ± 4 mg/dl, p < 0.01; creatinine, 2.1 ± 0.3 versus 0.3 ± 0.1 mg/dl, p < 0.01). Consistently, the renal histological changes induced by cisplatin were rescued significantly as compared with those in mice on NC (Fig. 7, C and D). Fig. 7E illustrates the effects of cisplatin on the production of 4-HNE in mice on NC and CR diets. Cisplatin markedly increased renal 4-HNE production in mice fed NC, which was partially restored in mice on a CR diet (Fig. 7, E and F). We further examined the effects of CR on the activation of downstream transcription factors of Sirt1 by quantitative reverse transcription-PCR. The mRNA expression of PPARα, PPARγ, and PGC-1α target genes, including MCAD and ACOX-1 was analyzed. These results were similar to those obtained in cisplatin-induced renal damages in TG mice (supplemental Figs. SIII and SIV).

**Effects of Renal I/R Injury in Sirt1-TG Mice**—We next examined the role of Sirt1 in renal I/R injury. Extensive tubular injuries were observed in WT kidneys 24 h after I/R. Overexpression of Sirt1, however, failed to protect against I/R injury. Neither renal function, as assessed by BUN and serum creatinine (Fig. 8A), nor renal histological findings were alleviated in Sirt1-TG mice, as compared with WT mice (Fig. 8B). Fig. 8C shows the effects of Sirt1 on the apoptotic process induced by I/R-induced AKI. Thus, I/R-induced TUNEL-positive cells were observed predominantly in the medulla rather than in the renal cortex, i.e. preferentially in S3 segmental proximal tubules rather than in cortical proximal S1 or S2 segments. Kidneys in TG mice after I/R had nearly the same amount of TUNEL-positive cells as in WT mice (14.3 ± 3.2 versus 13.7 ± 3.8 nuclei/high power field). In the immunofluorescence (IF), the number of peroxisomes was not affected by I/R, which were also unaltered in TG mice. On the other hand, the number of mitochondria was reduced by I/R, which was not ameliorated in TG mice.
Renal Sirt1 Protects against Acute Kidney Injury

Sirt1 prevented the decrease in peroxisome number induced by cisplatin treatment (Fig. 10B). However, in the assay for mitochondrial number by Mito-OFP fluorescence, Sirt1 did not alter the reduction in mitochondria number induced by I/R (Fig. 10C). These results are consistent with the results in cisplatin-induced AKI as well as in I/R-induced AKI. The present results also suggest that Sirt1 overexpression results in cisplatin-induced peroxisomal number reduction directly.

DISCUSSION

Although cisplatin is clinically used as an anti-cancer therapy, nephrotoxicity remains a critical problem. Pathologically, cisplatin is demonstrated to elicit predominantly proximal tubular injury. Previous investigations demonstrated that resveratrol up-regulated Sirt1 expression (23) and attenuated the cisplatin-induced AKI (24). In concert, these observations lend support to the hypothesis that the modulation of Sirt1 expression constitutes a molecular tool for the prevention of cisplatin-induced AKI.

The mechanism for the protective action of Sirt1 on cisplatin-induced AKI has not been assessed hitherto. It has been reported that cisplatin affects the peroxisome system, including the suppression of peroxisome number and function in kidney tissues of mice (11). The peroxisome is an organelle bound by a single membrane and is involved in metabolic processes, including peroxide-based respiration and oxidative degradation of fatty acids and purines (25). Furthermore, peroxisome eliminates excessive ROS and promotes FAO that is closely linked to the key system for ATP generation. The present study demonstrates that cisplatin causes a decrease in peroxisome number (i.e., PMP70; Fig. 4A) whose function as evaluated by a reduction in catalase expression (Fig. 4B) as well as the expression of ACOX1, a member of FAO systems (Fig. 4C) and the subsequent accumulation of 4-HNE (Fig. 4D). All of these parameters are well preserved in kidneys from TG mice. Indeed, we have recently demonstrated that Sirt1 prevents apoptosis through the induction of catalase in HK-2 cells (7). Catalase is located in peroxisome fraction, which has been shown to promote peroxisome proliferation (26); the supplementation of peroxisome activator nafenopin results in a sustained increase in the number of peroxisomes with concomitant increases in catalase activity (27). Increased catalase therefore may eliminate H$_2$O$_2$ within peroxisome, which possibly leads to the mitigation of the damages to peroxisome. Therefore, it appears that the protective effects of Sirt1 on the peroxisome enzyme are partially secondary to the induction of catalase and/or its resultant peroxisome proliferation. In concert, our study reveals that peroxisome is an important intracellular target organelle for Sirt1.

Peroxisomes are important organelles for the maintenance of vital function. It has been reported that mitochondria are altered in both number and function in cisplatin-induced AKI (12). In AKI, the elevated ROS level within mitochondria is deleterious to the cell because of their ability to induce lipid peroxidation, protein oxidation, and DNA damage. The increased ROS also damages mitochondria, which subsequently produces excessive ROS (28). In the present study, cisplatin injection reduces both mitochondrial DNA copy number.
Renal Sirt1 Protects against Acute Kidney Injury

and PGC-1α, a principle regulator for mitochondria biogenesis (Fig. 5, A and B). Nevertheless, TG mice did not exhibit the reversal of mitochondrial DNA copy number or PGC-1α expression. Alternatively, whereas cisplatin down-regulated the expression of mitochondria enzyme, MCAD, Sirt1 overexpression restored the MCAD expression, thus suggesting that mitochondria function was partially recovered by Sirt1 overexpression (Fig. 5C). Furthermore, as shown in 4-HNE staining (Fig. 4D), overexpression of catalase is capable of reducing H$_2$O$_2$ in peroxisome, which would diminish the cellular ROS and subsequently restore the mitochondrial β-oxidation enzyme system (Fig. 5C), with resultant ATP generation (Fig. 10). Because our cell culture study revealed that Sirt1 did not modify the mitochondrial number directly, the reversal of mitochondrial enzyme in TG mice was a secondary effect of the reduction in cellular ROS through the activation of the Sirt1-catalase system (Fig. 11).

The results of immuno-EM supported these results. Cisplatin induced the reduction in the number and morphological deformities of peroxisomes, which were reversed by Sirt1 overexpression. These changes in vivo are due to the direct effect of cisplatin and Sirt1 overexpression because these data are also consistent with the result of the in vitro study using HK-2 cells. However, the precise mechanism for the protective effect of Sirt1 on the morphological changes of peroxisomes needs to be examined. In contrast, mitochondrial number on immuno-EM was not altered with cisplatin, whereas mtDNA copy number was slightly changed, and PGC1α was remarkably reduced with cisplatin. This may suggest that the early biochemical changes such as PGC-1α, which preceded the morphological alterations (i.e., mtDNA copy number and mitochondria number observed on EM) were detected earlier in this model. Moreover, neither mtDNA copy number nor PGC1α were affected by Sirt1 overexpression.

Renal I/R injury is also a serious problem among AKI. Previous studies documented that peroxisome number and/or function were damaged in the kidneys of mice undergoing I/R injury (13). In the present study, however, we failed to demonstrate a beneficial effect of Sirt1 on the development of AKI when induced by I/R injury (Fig. 8, A and B). The reason for this observation is most likely explained by the difference in the affected cellular organelles between by the cisplatin insults and by I/R injury. Cisplatin mainly damaged peroxisomes as evident in immuno-EM (Fig. 6), whereas I/R did not affect peroxisomes much but damaged mitochondria predominantly (Fig. 9). Because Sirt1 rescues renal tubular damages mainly through the restoration of peroxisome number and function, Sirt1 may not be able to rescue

Renal Sirt1 Protects against Acute Kidney Injury

FIGURE 10. Effects of Sirt1 overexpression on peroxisome and mitochondria mass in HK-2 cells. A, apoptosis was determined by FACS. Each graph for FACS represents the population of the cells stained with annexin V (x axis) and propiumiodine (y axis) (upper panel). A bar graph summarizing the FACS results are shown in the lower panel. The data are the means ± S.E. *, p < 0.05 versus control. All of experiments were conducted three times using different cultures. B and C, representative confocal laser scanning microscopic images of Peroxi-GFP, for the assessment of peroxisome number (B) and Mito-OFP, for the assessment of mitochondrial number (C), in HK2 cells with or without cisplatin treatment or I/R model. The bar graph under each microscopic image represents the quantification of the average pixel intensity of Peroxi-GFP (B) or Mito-OFP (C). *, p < 0.05 versus untreated control cells (n = 4). Scale bars, 50 μm.
Renal Sirt1 Protects against Acute Kidney Injury

We have demonstrated that renal Sirt1 exerts protective action on AKI, possibly because of the preservation of peroxisome functions. These effects contributed substantially to the elimination of excessive ROS and to the recovery from mitochondria dysfunction. Our results provide firm evidence that the modalities modulating Sirt1 activity constitute attractive candidates for the treatment of peroxisome dysfunction-related AKI.

REFERENCES

1. Guarente, L. (2000) Genes Dev. 14, 1021–1026
2. Luo, J., Nikolaev, A. Y., Imai, S., Chen, D., Su, F., Shiloh, A., Guarente, L., and Gu, W. (2001) Cell 107, 157–148
3. Nemoto, S., Fergusson, M. M., and Finkel, T. (2004) Science 306, 2105–2108
4. Wiggins, J. E., Goyal, M., Sanden, S. K., Wharram, B. L., Shedden, K. A., Mizek, D. E., Kuick, R. D., and Wiggins, R. C. (2005) J. Am. Soc. Nephrol. 16, 2953–2966
5. Giovannini, L., Migliori, M., Longoni, B. M., Das, D. K., Bertelli, A. A., Panichi, V., Filippi, C., and Bertelli, A. (2001) J. Cardiovasc. Pharmacol. 37, 262–270
6. Alcendor, R. R., Gao, S., Zhai, P., Zablocki, D., Holle, E., Yu, X., Tian, B., Wagner, T., Ratner, S. F., and Sadoshima, J. (2007) Circ. Res. 100, 1512–1521
7. Hasegawa, K., Wakino, S., Yoshioka, K., Tatematsu, S., Hara, Y., Minakuchi, H., Washida, N., Tokuyama, H., Hayashi, K., and Itoh, H. (2008) Biochem. Biophys. Res. Commun. 372, 51–56
8. Brezniceanu, M. L., Liu, F., Wei, C. C., Chènier, L., Godin, N., Zhang, S. L.,...
